|
SUMO3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.45969911105703E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.08800002340814E-09 |
| Normal-vs-Stage2 |
3.37600000177574E-08 |
| Normal-vs-Stage3 |
2.2934000032393E-08 |
| Normal-vs-Stage4 |
6.1506999493588E-09 |
| Stage1-vs-Stage2 |
2.362200E-02 |
| Stage1-vs-Stage3 |
7.156200E-01 |
| Stage1-vs-Stage4 |
9.713600E-02 |
| Stage2-vs-Stage3 |
8.995700E-02 |
| Stage2-vs-Stage4 |
6.053000E-01 |
| Stage3-vs-Stage4 |
2.310400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.4588000786282E-10 |
| Normal-vs-AfricanAmerican |
8.221800E-04 |
| Normal-vs-Asian |
5.93859994513224E-09 |
| Caucasian-vs-AfricanAmerican |
5.207600E-01 |
| Caucasian-vs-Asian |
2.399200E-01 |
| AfricanAmerican-vs-Asian |
1.596020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.89330004188804E-09 |
| Normal-vs-Female |
2.35439445717134E-11 |
| Male-vs-Female |
7.216400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.32479999695556E-08 |
| Normal-vs-Age(41-60Yrs) |
1.18629550627247E-11 |
| Normal-vs-Age(61-80Yrs) |
3.18490001038896E-09 |
| Normal-vs-Age(81-100Yrs) |
7.912300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.485600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.682770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.164600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.994000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.687850E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.196800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.616600E-01 |
| Classical-VS-Follicular |
1.340100E-02 |
| Classical-VS-Other |
2.923800E-01 |
| Classical-VS-Normal |
2.25440000001242E-08 |
| Tall-VS-Follicular |
2.319000E-01 |
| Tall-VS-Other |
5.295200E-01 |
| Tall-VS-Normal |
1.56025999999976E-05 |
| Follicular-VS-Other |
9.648800E-01 |
| Follicular-VS-Normal |
2.12200002014384E-09 |
| Other-VS-Normal |
1.462480E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.3270000350002E-10 |
| Normal-vs-N1 |
1.25279786544752E-11 |
| N0-vs-N1 |
1.770060E-02 |
|
|
